Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Effect of hypertension (HTN) on progression-free survival (PFS) in patients (pts) receiving front-line bevacizumab (BEV) for primary advanced ovarian cancer (OC) in the NOGGO single-arm OTILIA study: A post hoc analysis in 808 pts.

Armbrust, R., Wimberger, P., Mustea, A., Oskay-Özcelik, G., Keller, M., Richter, R., Harde, J., Zortel, M., Wegenaer, A., Tome, O., Sehouli, J., North-Eastern German Society of Gynaecological Oncology (NOGGO), 2018.

J Clin Oncol (Meeting Abstracts) 36 (suppl) abstr 5546.

Abstract

Indikation: Other, Ovarialkarzinom, Ovarian Cancer, Sonstige / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
OTILIA
2018
The Prospective Intersectoral National Cohort Study MYRIAM To Study Characteristics, Treatment And Outcome Of Patients With Multiple Myeloma In Germany.

Knauf, W., Engelhardt, M., Losem, C., Lipke, J., Kasper, C., Houet, L., Vannier, C., Jänicke, M., Marschner, N., Dechow, T., Einsele, H., 2018.

HemaSphere 2(S1)(PB2162), 967.

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: EHA / Journal: -
MYRIAM
2018
MANTA – A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer.

Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., Makris, A., Nemsadze, G., Brunt, A.M., Kuemmel, S., Cabrero, I.R., Perelló, A., Kendall, A., Brown, J., Kristeleit, H., Conibear, J., Saura, C., Grenier, J., Máhr, K., Schenker, M., Sohn, J.H., Lee, K.S., Sarker, S.-J., Coetzee, C., Mousa, K., Castan, J.C., 2018.

Cancer Res 78(4 Supplement), GS2-07-GS2-07. doi:10.1158/1538-7445.SABCS17-GS2-07

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
MANTA
2018
Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.

Knauf, W., Aldaoud, A., Losem, C., Mittermueller, J., Neise, M., Niemeier, B., Harde, J., Trarbach, T., Potthoff, K., 2018.

Leuk. Res. 68, 90–97. doi:10.1016/j.leukres.2018.03.008

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: Leukemia Research
Revlimid-NIS
2018
Prophylaxis of Chemotherapy-induced Neutropenia and Febrile Neutropenia with Lipegfilgrastim in Patients with Non-Hodgkin Lymphoma (NADIR study).

Wolff, T., Schulz, H., Losem, C., Reichert, D., Hurtz, H.-J., Sandner, R., Harde, J., Grebhardt, S., Potthoff, K., Mueller, U., Fietz, T., 2019.

Eur J Hematol. doi:10.1111/ejh.13189

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: European Journal of Hematology
NADIR
2018
Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC-Registry.

Goebell, P.J., Staehler, M., Müller, L., Nusch, A., Scheffler, M., Sauer, A., von Verschuer, U., Tech, S., Kruggel, L., Jänicke, M., Marschner, N., RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma), 2018.

Clin. Genitourin. Cancer. 16, e1101-e1115.https://doi.org/10.1016/j.clgc.2018.06.006

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: Clinical Genitourinary Cancer
TNK
2018
Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-Registry.

Goebell, P.J., Müller, L., Hübner, A., Harich, H.-D., Boller, E., Koska, M., Jänicke, M., Marschner, N., RCC-Registry Group (Tumour Registry of Advanced Renal Cell Carcinoma), 2018.

Urol. Oncol. 36, 470.e1-470.e9. https://doi.org/10.1016/j.urolonc.2018.07.007

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: Urologic Oncology
TNK
2018
Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).

Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Niemeier, B., Harde, J., Hannig, C.V., Harich, H.-D., Müller, J., Klausmann, M., Tessen, H.W., Potthoff, K., 2018.

Eur J Haematol 101(6), 766–773. doi:10.1111/ejh.13160

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: - / Journal: European Journal of Hematology
PIAZA
2018
Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.

Boegemann, M., Bedke, J., Schostak, M., Welslau, M., Hering-Schubert, T., Wolf, T., Schleicher, J., Ehness, R., Klein, D., Medinger, T., Goebell, P., 2018.

Oncol Res Treat 41 (suppl4)(P602), 201-202.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
PAZOREAL
2018
705 patients with metastatic breast cancer treated with nab-paclitaxel: Results of the non-interventional study NABUCCO.

Potthoff, K., Nusch, A., Söling, U., Hansen, R., Salat, C., Grebhardt, S., Harde, J., Marschner, N. 2018.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal:
NABUCCO
2018